Targeted Therapeutics Peel Therapeutics focuses on first-in-class neutrophil targeting peptides and nanotechnology for cancer and inflammatory diseases, presenting a potential opportunity to offer contract research, peptide synthesis partnerships, and companion diagnostics for targeted therapies.

Clinical Development With a clinical stage pipeline and a recent seed financing round, there is a need for CRO partnerships, clinical trial materials, scalable manufacturing processes, and regulatory strategy support to accelerate Phase I/II programs.

Strategic Financing Significant fundraising activity and non-dilutive NIH-SBIR/STTR funding indicate potential for services that align with grant preparation, portfolio financing insights, and grant management platforms to optimize capital efficiency.

Solubility and Bioavailability Peels emphasis on solubility, scalability, and bioavailability suggests opportunities in formulation development, analytic characterization, and advanced delivery platforms to improve translational success and patient outcomes.

Digital & Cloud Reliance on cloud and web technologies plus a relatively lean team implies potential value in cloud-based data management, AI-driven research analytics, and cybersecurity/compliance solutions tailored to biotech startups.